A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Trial Profile

A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Tesevatinib (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Kadmon Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Aug 2016 According to a Kadmon Corporation media release, first patient has been dosed in this study.
    • 29 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top